Answers are grounded in this paper and cite their sources.
Randomized trial shows improved glycemic control in adults with type 2 diabetes, indicating a potential new treatment option.
Introduction and Objective: The efficacy and safety of the daily oral, non-peptide GLP-1RA orforglipron (OFG) were assessed as add-on to insulin glargine with/without metformin and/or SGLT-2 inhibitors in adults with type 2 diabetes (T2D) (ACHIEVE-5; NCT06109311). Methods: In this 40-week double-blind, randomized, placebo-controlled, phase 3 study, participants with T2D and inadequate glycemic control were randomized (1:1:1:1) to receive daily OFG (3, 12, or 36 mg) or placebo (PBO). The primary endpoint was change from baseline in HbA1c at week 40 (superiority for 12 and/or 36 mg). Results are presented for the efficacy estimand. Results: 546 participants (age 60.2 years; T2D duration 15.0 years; HbA1c 8.5% [69.4 mmol/mol]; BMI 30.8 kg/m2) were randomized. At week 40, all OFG doses were superior to PBO in the primary and all key secondary endpoints (all p <0.001). Mean HbA1c decreased by 1.54 to 2.05% in the OFG groups vs 0.77% with PBO. Bodyweight change ranged from -2.7% to -6.1% with OFG vs 0.6% with PBO. The most frequent adverse events were gastrointestinal and occurred mostly during escalation. Rates of Level 2 hypoglycemia were similar between OFG and PBO. Severe hypoglycemia was reported by 2 participants in the OFG 12 mg group and 1 participant in the OFG 36 mg group. Conclusion: OFG added to titrated basal insulin improved glycemic control and reduced bodyweight without increasing hypoglycemia risk in patients with long-standing T2D. Disclosure F. Giorgino: Advisory Panel; Current; Abbott. Consultant; Current; Lilly, Novo Nordisk. Advisory Panel; Current; AstraZeneca, Medtronic. Research Support; Current; Roche Diabetes Care. Advisory Panel; Current; LifeScan, Sanofi. Advisory Panel; Ended; Merck Sharp & Dohme Corp. Advisory Panel; Current; Boehringer Ingelheim International GmbH. S. Dsouza: Consultant; Current; Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Consultant; Current; Novo Nordisk. Speaker's Bureau; Current; Novo Nordisk. Consultant; Current; Madrigal Pharmaceuticals, Inc. Speaker's Bureau; Current; Madrigal Pharmaceuticals, Inc. L. Ludwig: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. A. Kiyosue: None. S.M. Ibriga: Employee; Current; Eli Lilly and Company. H. Rha: Employee; Current; Eli Lilly and Company. R. Liu: None. M. Denning: Employee; Current; Eli Lilly and Company. J. Tobian: Employee; Current; Eli Lilly and Company.
No takes yet. Share an insight, caveat, or question.
GIORGINO et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: